Lyell Immunopharma, Inc.'s financials show reduced losses and efficient cash management, with a strong cash position supporting operations through 2027 despite a challenging biotech environment ...

Lyell Immunopharma (LYEL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Lyell Immunopharma, Inc SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR ...

No dose-limiting toxicities have been reported in patients without lung involvement. Pneumonitis occurred in patients with lung metastases and dose escalation continues separately and more ...